Human IL-29/IFN-lambda 1 Antibody, R&D Systems™

IL-29/IFN-lambda 1

Monoclonal

LYOPH

Neutralization 1-4 ug/mL, ELISA Capture (Matched Antibody Pair) 2-8 ug/mL

Q8IU54

IFNL1

Mouse myeloma cell line NS0-derived recombinant human IL-29/IFN-lambda 1 Gly20-Thr200 Accession # Q8IU54

100 μg

Primary

Detects human IL-29/IFN-lambda 1 in ELISAs. In sandwich immunoassays, 100% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and 20% with rhIL-28A is observed. No cross-reactivity or interference was observed with rhIFN-alpha A, rhIFN-alpha B2, rhIFN-alpha G, rhIFN-alpha I, or rhIFN-beta 1A.

Human

Supernatant

Neutralization, ELISA

247801

Unconjugated

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative

cytokine Zcyto21, IFNL1, IFNl3, IFNlambda 1, IFN-lambda 1, IFNlambda 3, IFN-lambda 3, IFN-lambda-1, IL29, IL-29, interferon lambda-1, interferon, lambda 1, interleukin 29 (interferon, lambda 1), interleukin-29, ZCYTO21

Mouse

Protein A or G purified from hybridoma culture supernatant

RUO

282618

Reconstitute at 0.5 mg/mL in sterile PBS.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.

IgG2a